EUROFINS-SCIENTIFIC
9.12.2020 08:02:11 CET | Business Wire | Press release
In response to increasing global demand for virucidal testing services in the wake of COVID-19, Eurofins BioPharma Product Testing Italy (Eurofins BTP Italy) has expanded its virucidal testing capacity with the opening of a dedicated laboratory, in its Milan campus. The laboratory will carry out testing and studies on disinfectant products.
Delivered in just 3 months, the 400sqm BioSafety Level 2 laboratory is now fully complete and commissioned, all required staff and scientists were recruited and trained in parallel to allow for operations to commence as of the beginning of December 2020.
Disinfectant products have become pervasive in our daily lives as a result of COVID-19, being used much more widely and frequently than before. Demand for such products has increased significantly, as have testing requirements. The laboratory will host ISO 17025 accredited tests and Good Laboratory Practices (GLP) studies to assess and demonstrate the general virucidal activity (against enveloped and/or non-enveloped viruses) of products and determine efficacy levels against Coronaviruses or Influenza. Tests are performed following international validated standards and guidance; CEN, ISO, ASTM and OECD. With 8 biohazard virucidal workstations and cell culture manipulation testing equipment, the laboratory will increase Eurofins BPT Italy’s virucidal study capacity from 40 to 100 studies per month. The laboratory has been designed in such a way that will allow for expansion to double testing study capacity as and when required. It has also been designed to facilitate current COVID-19 social distancing health and safety measures.
Eurofins BPT Italy, an 18,000sqm campus in Milan, employs 350 people and provides laboratory testing and research services to the disinfectant, medical device and pharmaceutical industries. Our experts have over 20 years’ experience in assessing the efficacy of disinfectant products against microorganisms and viruses.
The facility is GLP certified, EN ISO/IEC 17025 accredited, Good Manufacturing Practice (GMP) accredited by the Italian drug agency, AIFA, and audited by the North American Food and Drug Administration (FDA). The new virucidal testing laboratory will allow Eurofins BPT Italy to continue supporting clients in their development and regulatory testing activities.
For further information: https://www.eurofins.com/COVID-19-virucidal-testing
About Eurofins – the global leader in bio-analysis
With over 50,000 staff across a network of more than 800 laboratories in over 50 countries , Eurofins’ companies offer a portfolio of over 200,000 analytical methods.
Eurofins Shares are listed on Euronext Paris Stock Exchange.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201208005057/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Navan Unlocks Savings for Travelers with First SAS NDC Direct Connect28.5.2026 09:01:00 CEST | Press release
Direct connection gives travelers access to lower fares and streamlined post-booking services Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced a New Distribution Capability (NDC) integration with Scandinavian Airlines (SAS). By allowing the airline to share its fares, availability, and offers directly in real time, the integration provides an expanded portfolio of SAS fares and services to Navan customers. This makes Navan the first Travel Management Company (TMC) to access SAS NDC content via a direct connection, leveraging version 21.3 of the NDC API. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260528812727/en/ Direct connection gives travelers access to lower fares and streamlined post-booking services “Our Modern Airline Retailing journey is centered on delivering more relevant offers, greater transparency, and better value for travelers,” said Edward Fotheringham, VP S
KKR to Open New Office in Milan, Strengthening Long-Term Commitment to Italy28.5.2026 09:00:00 CEST | Press release
New office reflects KKR’s localisation strategy and opportunity in Italy’s evolving investment landscape KKR, a leading global investment firm, today announced plans to open an office in Milan, further strengthening its long-term commitment to Italy and expanding its local presence in one of Europe’s largest economies. The office will support the firm’s investment activity across Private Equity, Real Assets, Credit and Insurance, while deepening client partnerships and advancing the continued development of KKR’s private wealth business in Italy. Italy has been an important market for KKR for over two decades, with over €10 billion of capital deployed since 2005 across Private Equity, Real Assets and Credit. The firm’s investments include FiberCop, Europe’s first wholesale-only, open-access fibre network, Enilive, a key player in advancing Italy’s energy transition, and CMC, a sustainable packaging leader using robotics to drive innovation. These investments reflect KKR’s focus on part
Merz Therapeutics Presents New Research at World Parkinson Congress 2026, Revealing the Hidden Burden of "OFF" Episodes in Parkinson’s Disease28.5.2026 09:00:00 CEST | Press release
A new qualitative literature review provides a comprehensive model of the patient experience of OFF episodes, identifying 132 distinct motor, non-motor and quality-of-life impacts1 The research highlights OFF episode as a complex, multifaceted experience, highlighting the profound and often invisible struggles faced by people with Parkinson’s disease1 Additional analyses of levodopa inhalation powder (INBRIJA®) confirm its clinical profile as a rapid, reliable and well-tolerated on-demand treatment for OFF episodes2,3 Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new research at the World Parkinson Congress (WPC) 2026 that uncovers the multifaceted burden of "OFF" episodes in Parkinson's disease (PD). The qualitative literature review demonstrates that these episodes are not only a re-emergence of motor symptoms, but also a complex mix of debilitating motor and non-motor symptoms that impact the lives of people with Parki
Navan Strengthens European Train Offering with Swedish Rail Integration28.5.2026 09:00:00 CEST | Press release
Through a direct connection with SilverRail, Navan adds more than 20 Swedish rail carriers to its long list of European rail options Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced the addition of more than 20 Swedish rail carriers to its platform, including Sweden’s largest operators, SJ and VR. Powered by SilverRail's global rail distribution platform, the API integration unlocks access for Navan customers to domestic rail routes in Sweden, as well as many popular cross-border routes in the region, such as between Stockholm and Copenhagen. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260528696890/en/ Through a direct connection with SilverRail, Navan adds more than 20 Swedish rail carriers to its long list of European rail options “We’re seeing strong momentum in Sweden,” says Michael Riegel, Chief Customer Officer at Navan. “It’s a unique economy where you have this inte
SMBC and Toshiba Jointly Develop New Equity Indices Using Advanced Quantum-Driven Technologies28.5.2026 03:00:00 CEST | Press release
Sumitomo Mitsui Banking Corporation (“SMBC”) and Toshiba Corporation (“Toshiba”) today announced the joint development of the SMBC/TOSHIBA Quantum Driven Diversified Japan Equity Index and the SMBC/TOSHIBA Quantum Driven Diversified U.S. Equity Index, new equity indices realized with advanced quantum-driven technologies. Collectively, the indices are referred to as “SMBC/TOSHIBA Quantum Diversified” (the “Indices”). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260519448161/en/ Toshiba’s Simulated Bifurcation Machine 1. Background and Objectives Equity investment is central to asset management, but it also carries the ever-present risk of abrupt and substantial market fluctuations driven by geopolitical developments, changes in economic policy, and other external factors. In uncertain markets, investors are constantly seeking innovations in risk diversification that can protect their assets from unexpected market shocks. SM
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom